Gene therapy: progress and predictions.

Mary Collins, Adrian Thrasher

Journal: Proceedings. Biological sciences 2017;282(1821):20143003

PMID: 26702034

Abstract

The first clinical gene delivery, which involved insertion of a marker gene into lymphocytes from cancer patients, was published 25 years ago. In this review, we describe progress since then in gene therapy. Patients with some inherited single-gene defects can now be treated with their own bone marrow stem cells that have been engineered with a viral vector carrying the missing gene. Patients with inherited retinopathies and haemophilia B can also be treated by local or systemic injection of viral vectors. There are also a number of promising gene therapy approaches for cancer and infectious disease. We predict that the next 25 years will see improvements in safety, efficacy and manufacture of gene delivery vectors and introduction of gene-editing technologies to the clinic. Gene delivery may also prove a cost-effective method for the delivery of biological medicines.

© 2015 The Authors.

Address: Division of Infection and Immunity, University College London, Gower Street, London WC1E 6BT, UK Division of Advanced Therapies, National Institute for Biological Standards and Control, Blanche Lane, Potters Bar, Herts EN6 3QG, UK [email protected].; Institute of Child Health, University College London, Gower Street, London WC1E 6BT, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.